Drugs News and Research

RSS

Eliminating copayments for high-value prescription drugs improves employees' adherence to treatment regimens

An initiative by the U. S. technology company Pitney Bowes to make medications of proven value less expensive for their employees succeeded in stabilizing employees' adherence to their treatment regimens, according to a Commonwealth Fund-supported study published in this month's Health Affairs.

3 Nov 2010

New technique could help scientists to predict how living prostate tissues respond to therapy

Scientists at the Johns Hopkins Kimmel Cancer Center, University of Helsinki and Stanford University have developed a technique to keep normal and cancerous prostate tissue removed during surgery alive and functioning normally in the laboratory for up to a week.

3 Nov 2010

Study finds risk of toxicity in Phase I radiation oncology clinical trials

Risks to patients enrolled in Phase I radiation oncology clinical trials are higher than previously appreciated, according to a study conducted by researchers from the Kimmel Cancer Center at Jefferson. The findings will be presented at the American Society of Radiation Oncology (ASTRO) annual meeting in San Diego.

3 Nov 2010

Pharma companies in Asia Pacific shift to high-risk, high-return research and development

Pharmaceutical companies in the Asia Pacific region are increasingly adapting their business models from the production of generic drugs towards more high-risk, high-return research and development, according to a new report released today by CMR International, a Thomson Reuters business.

3 Nov 2010

OMJPI enters agreement with Watson to distribute generic version of CONCERTA tablets

Ortho-McNeil-Janssen Pharmaceuticals, Inc. today announced it has entered into a supply and distribution agreement with Watson Laboratories, Inc. to distribute an authorized generic version of CONCERTA (methylphenidate HCl extended-release tablets).

3 Nov 2010

CVS Caremark supports FDA pathway for approval of biogeneric options

CVS Caremark reiterated the company's support that the U.S. Food and Drug Administration (FDA) implement regulations necessary to approve biogeneric drugs under the Affordable Care Act. The company's Senior Vice President of Specialty Pharmacy Operations, Scott Reid, testified before the FDA today during a public hearing to address the development of an approval pathway for biosimilar and interchangeable biological products held at the agency's headquarters in Silver Spring, Maryland.

3 Nov 2010

Researchers discover FoxO1 protein interacts with macrophages to promote inflammatory response

Researchers at the University of California, San Diego School of Medicine have discovered that a multi-tasking protein called FoxO1 has another important but previously unknown function: It directly interacts with macrophages, promoting an inflammatory response that can lead to insulin resistance and diabetes. Contrarily, it also generates a negative feedback loop that can limit damage from excessive inflammation.

3 Nov 2010

Avila presents results of AVL-192 preclinical studies for HCV infection at AASLD Meeting

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, presented results today of preclinical studies that demonstrate its orally-available targeted covalent drug candidate, AVL-192, achieves superior potency against drug-resistant mutations of the Hepatitis C Virus (HCV). These new data were presented today at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) international meeting in Boston, Massachusetts.

3 Nov 2010

JenaValve commences CE-Mark study for transapical TAVI system

JenaValve™ Technology, Inc., a medical device company specialized in developing transcatheter valve replacement products, announced today the start of its multicenter CE-mark study. The first two implantations of its transapical TAVI system were performed by Dr. med. Hendrik Treede at the Universitäres Herzzentrum Hamburg.

3 Nov 2010

Insuring your health: Seniors should consider changes in Medicare Part D plans

In her latest Kaiser Health News consumer column, Michelle Andrews writes: "If you're on Medicare Part D, this month marks the beginning of the annual enrollment time when beneficiaries can try to pick the plan that provides the best coverage for their prescription drugs.

3 Nov 2010

UK watchdog agency to lose power to reject new drugs

The British government is expected to strip the National Institute for Health and Clinical Excellence, or NICE, of its ability to reject new drugs.

3 Nov 2010

CytRx receives nontaxable grant under Qualifying Therapeutic Discovery Project Program

CytRx Corporation a biopharmaceutical company specializing in oncology, today announced that it has been awarded a nontaxable grant of approximately $735,000 related to its INNO-206, tamibarotene and bafetinib programs under the Qualifying Therapeutic Discovery Project Program included in the Patient Protection and Affordable Care Act, H.R. 3590, signed into law in March 2010.

3 Nov 2010

Medicare Roundup: Courts widen coverage of skilled care; experts give enrollment advice

Two federal courts have ruled that the Obama administration is using overly strict standards to determine whether older Americans are entitled to Medicare coverage of skilled nursing home care and home health care.

3 Nov 2010

Advanced Life Sciences enters CRADA for Restanza with Walter Reed Army Institute of Research

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that it has entered into a Cooperative Research and Development Agreement ("CRADA") with The Walter Reed Army Institute of Research.

2 Nov 2010

Medco third quarter net revenue increases 10.3% to $16.3 billion

Medco Health Solutions, Inc. today reported record third-quarter 2010 GAAP diluted EPS of $0.85, up 23.2 percent compared to $0.69 for the third quarter of 2009. Adjusting for the amortization of intangible assets that existed when Medco became a publicly traded company in 2003, third-quarter 2010 diluted earnings per share increased 21.3 percent to a record $0.91, from $0.75 in the third quarter of 2009.

2 Nov 2010

RegeneRx announces positive results from RGN-259 non-clinical study for Dry Eye Syndrome

RegeneRx Biopharmaceuticals, Inc. today announced the results of its first non-clinical dry eye study using RGN-259, RegeneRx's ophthalmic, preservative-free eye drop for the treatment of Dry Eye Syndrome (DES). In the study, animals were treated with RGN-259, a vehicle control and a positive control, doxycycline.

2 Nov 2010

TriRima shows positive result in food-induced cardiovascular effects associated with MAO inhibitors

CeNeRx BioPharma, Inc., today announced that a new formulation of TriRima, its lead agent for treatment resistant depression, showed excellent safety in a study designed to test whether it is free of the food-induced cardiovascular effects associated with conventional MAO inhibitors.

2 Nov 2010

First Edition: November 2, 2010

Today's headlines highlights news stories that include speculation about what will become of the health reform law after the election.

2 Nov 2010

New targeted therapy shows positive results in patients with lung cancer

A UC Irvine oncologist's work with a targeted therapy is showing great promise in patients with a deadly form of lung cancer. The results were published Thursday in the New England Journal of Medicine.

2 Nov 2010

NSAIDs drugs prevent colon cancer: Research

Nonsteroidal anti-inflammatory drugs (NSAIDs) prevent colon cancer by triggering diseased stem cells to self-destruct, according to researchers at the University of Pittsburgh Cancer Institute (UPCI) and the University of Pittsburgh School of Medicine.

2 Nov 2010

Drugs News and Research

Eliminating copayments for high-value prescription drugs improves employees' adherence to treatment regimens

New technique could help scientists to predict how living prostate tissues respond to therapy

Study finds risk of toxicity in Phase I radiation oncology clinical trials

Pharma companies in Asia Pacific shift to high-risk, high-return research and development

OMJPI enters agreement with Watson to distribute generic version of CONCERTA tablets

CVS Caremark supports FDA pathway for approval of biogeneric options

Researchers discover FoxO1 protein interacts with macrophages to promote inflammatory response

Avila presents results of AVL-192 preclinical studies for HCV infection at AASLD Meeting

JenaValve commences CE-Mark study for transapical TAVI system

Insuring your health: Seniors should consider changes in Medicare Part D plans

UK watchdog agency to lose power to reject new drugs

CytRx receives nontaxable grant under Qualifying Therapeutic Discovery Project Program

Medicare Roundup: Courts widen coverage of skilled care; experts give enrollment advice

Advanced Life Sciences enters CRADA for Restanza with Walter Reed Army Institute of Research

Medco third quarter net revenue increases 10.3% to $16.3 billion

RegeneRx announces positive results from RGN-259 non-clinical study for Dry Eye Syndrome

TriRima shows positive result in food-induced cardiovascular effects associated with MAO inhibitors

First Edition: November 2, 2010

New targeted therapy shows positive results in patients with lung cancer

NSAIDs drugs prevent colon cancer: Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News